Finasteride, a common hormone-blocking drug, reduces men’s risk of getting prostate cancer without increasing their risk of dying from the disease, according to long-term follow-up data.
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
